CDK4 and neoplasm: In addition, recent evidence demonstrates that treatment of tumors with CDK4/CDK6 inhibitors could restore regulatory mechanisms, including regulation of IFNγ signaling, antigen presentation machinery and cell release of immunomodulating factors, leading to improve the immune anti-tumor activity [65].